Federal Register Notice: FDA is announcing the availability of grant funds for supporting the efforts of CDER. The agency intends to accept and consider a single-source application for awarding a grant to the Multiple Myeloma Service of Memorial Sloan Kettering Cancer Institute to support development of appropriate methodologies to conduct clinical trial design evaluation and determine extrapolation of findings from the general population to the U.S. black population. It aims to characterize the molecular subtypes of multiple myeloma in patients of black/African ancestry and investigate the effect of these on prognosis and novel therapy outcomes. To view this notice, click here.